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1. Introduction 
Acute coronary syndrome is a clinical condition of partial or total obstruction of blood flow 
in the coronary artery due to acute thrombus formation. Culprit vessel, coronary artery 
segment within which the site of origin of thrombus formation lies, is occupied by eroded or 
ruptured atherosclerotic plaque. Direct contact between circulating blood constituent and 
atherosclerotic plaque content owing to loss of endothelial cell barrier orchestrates the 
haemostasis events, i.e. thrombus formation and coagulation activation. Evolved within 
years of human life span, atherosclerotic undergoes three main steps: initiation, progression 
and finally complication (Libby, 2002).   
Atherosclerotic plaque development involves cellular and molecular interactions as well as 
blood flow dynamic alterations in the affected area. Although these steps affect all 
individual, some gather the risk factors to develop progression and complication of 
coronary atherosclerotic lesion faster and more prominent than others. Given the dynamic 
nature of these steps, understanding several mechanisms engage in every step will provide 
insight into therapeutic approach. Here, we review the last two steps of coronary 
atherosclerotic plaque development, with the focus in the role of platelets, anucleated cells 
being the target for therapeutic advancement in atherosclerosis and acute coronary 
syndrome.   
2. Formation of atherosclerotic plaque 
The earliest event of atherosclerosis formation is the retention of apolipoprotein B–
containing lipoproteins from circulation into subendothelial of the arterial wall (Tabas et al., 
2007). This particular lipoprotein interacts with subendothelial proteoglycan through ionic 
affinity and hence instigates lipoprotein retention in the intimal layer, the innermost part of 
the arterial wall (Borén et al., 1998; Skalen et al., 2002). During this stage, the tendency of 
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retention of lipoprotein depends greatly on sustained plasma level of apolipoprotein B-
containing lipoproteins and, in the lesser degree, lipoprotein size, charge, and composition 
as well as endothelial permeability (Tabas et al., 2007). Three classes of lipoproteins have 
apolipoprotein B as integral constituent: very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IDL), and low density lipoproteins (LDL) (Sniderman et al., 1991). 
Among them, LDL has the biggest apolipoprotein B proportion and is the most likely to 
interact with subendothelial proteoglycan  (Sniderman et al., 1991).  
Modification of LDL apolipoprotein B entrapped in intimal layer by oxidative mechanism 
results in oxidative LDL (oxLDL) (Stocker & Keaney, 2004). Smooth muscle cells, endothelial 
cells and macrophages are capable to modify LDL via oxidative modification (Diaz et al., 
1997). OxLDL is susceptible to scavenging macrophages and gives rise to the generation of 
cholesterol-laden foam cells (Stocker & Keaney, 2004). OxLDL continuously activates 
adjacent endothelial cells. Activated endothelial cells express adhesion molecules on their 
luminal surfaces which attract inflammatory cells from circulation, mainly monocytes and 
lymphocytes which transmigrate to intimal layer. The blend of inflammatory and resident 
vascular cells promotes the formation of atherosclerotic plaque. Arterial smooth muscle cells 
proliferate and migrate to the intimal layer in response to several growth factors releasing 
from chronic inflammation microenvironment in the intimal layer (Libby, 2002). Smooth 
muscle cells form a layer which envelopes the core of “inflammatory nidus” at the 
endothelial site, produce and release collagen and thus shape the so called fibrous cap. 
Below the cap, “inflammatory nidus” continuously attracts circulating LDL, modifies it and 
recognizes it as antigen which attracts more inflammatory cells.     
Atherosclerotic plaque mainly composes of two constructions which undergo dynamic 
changes: fibrous cap and lipid-rich core. The theories of how plaque originated have been 
proposed. Response-to-injury theory proposes the initial step in atherogenesis is endothelial 
denudation due to injurious substance or forces leading to alteration of normal vascular 
homeostatic properties (Ross, 1993). Injury to endothelial cells enhances endothelial 
permeability and adhesiveness for leukocytes to attach and migrate into subendothelial. 
Here inflammation occurs and macrophage recruitment and platelet adhesion and 
aggregation take place, which promote procoagulant tendency of the plaque. Response-to-
retention theory suggests LDL retention into subendothelial is the initial event and the 
prerequisite for plaque to form (Tabas et al., 2007). Endothelial injury does not play 
important role in this process, since plasma LDL is capable to cross normal endothelial cells 
through transcytosis mechanism and retains in subendothelial (Simionescu & Simionescu, 
1993). Subsequent events are monocyte recruitment and lipid-laden macrophage formation 
which initiate subendothelial inflammation (Tabas et al., 2007).  Oxidative modification 
theory indicates that to initiate plaque formation, subendothelial LDL should be modified 
chemically in order to attract macrophages’ scavenger receptor and be internalized to form 
foam cells (Stocker & Keaney, 2004). Native plasma LDL can enter subendothelial and is 
taken up by resident vascular cells via LDL receptor-mediated endocytosis. This native LDL 
does not initiate an inflammatory response and is not phagocytosed by monocytes, thus 
does not induce atherosclerosis (Torzewsky & Lackner, 2006).  
As the plaque progress, fibrous cap is thinner and turn out to be fragile due to the imbalance 
of extracellular matrix metabolism, the infiltration of the fibrous cap by macrophages and 
foam cells, and the calcification process (Burnier et al., 2009). All of these contribute to 
fibrous cap weakening and lost its protective role. Once fibrous cap lose its integrity, it 
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exposes thrombogenic plaque to circulation. Platelets, around 150,000 until 450,000 per 
millilitre circulate in the blood without contacting endothelial cells, adhere to exposed site, 
are activated and initiate the event to seal the broken plaque surface. Unfortunately, this 
process gives rise to thrombus formation and acute coronary syndrome.   
3. Activated platelet promotes progression of the plaque 
Putative notion that platelets have role merely in the complicating stage of atherosclerosis 
has recently been challenged by several evidence indicating the wider involvement of 
platelets in both early and late atherosclerosis steps (Ruggeri, 2002; Gawaz et al., 2005). In 
histopathology study of human atherosclerosis, platelets were observed in the lesions, both 
in the free form and derivative form being phagocytozed by foam cells and macrophages 
(Sevitt, 1986). Platelet patrols the blood circulation ensuring the integrity of endothelial cells. 
Once this integrity disrupts, platelets expose to subendothelial component and rapidly 
undergo activation to form haemostasis thrombus; this is the case of plaque erosion or 
rupture in acute coronary syndrome. However, intact yet activated endothelial cells can also 
promote platelet activation, this is the case of progressed atherosclerosis plaque.  
3.1 Role of platelet in progressed plaque dynamic 
Advanced responses to modified apolipoprotein B-containing LDL through chronic and 
maladaptive inflammation, macrophage and foam cell apoptotic and plaque necrotic 
formation are representatives of progressed plaque (Tabas et al., 2007). Endothelial cells 
lining the plaque are continuosly under activated state and express adhesion molecules and 
chemoattractant mediator in their surface. Monocytes and lymphocytes are attracted and 
adhere to these molecules and mediators, enter subendothelial and advance inflammatory 
state in the “inflammatory nidus” of the plaque (Lusis, 2000).  
The histomorphology of progressed plaque is characterized by the presence of large lipid-
rich necrotic core, and a thin fibrous cap. Fibrous cap composes mainly of extracellular 
matrix produced by vascular smooth muscle cells (Lusis, 2000). Supportive function of 
fibrous cap relies on the integrity of this matrix which is maintained through fine balance 
between matrix production and degradation (Ross, 1993). In progressed plaque, the matrix 
degradation activity is increased in line with inflammatory activity in the “inflammatory 
nidus” of the plaque below the cap. Macrophage-derived proteases degrade extracellular 
matrix, thus weaken fibrous cap (Ross, 1993).  
Necrotic core of progressed plaque is derived from foam cells that endure apoptosis and 
necrotic. Initially, necrosis core is an acellular lipid-rich core, which predominantly consist 
of deposited lipids, such as cholesterol esters and free cholesterol derived mostly from retain 
LDL particles (Lusis, 2000). High toxicity of LDL oxidation and formation of reactive oxygen 
species damage the surroundings vascular cells, including foam cells (Madamanchi et al., 
2005). The death of foam cells discharges extracellular lipids and cell debris into adjacent 
environments, thus promotes necrotic core formation (Lusis, 2000). Necrotic core enlarges 
and, in addition to free cholesterol, composes of cholesterol crystals, hyalinized hemorrhage 
and foam cell necrotic remnants (Virmani et al., 2000). Intimal calcifications, resulting from 
advance lipid oxidation and inflammatory cytokine reaction which modify osteogenic 
regulatory genes to promote osteogenesis, scatter in the base of necrotic core adjacent to the 
medial layer (Virmani et al., 2000; Abedin et al., 2004). Neovascularization in the intimal and 
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medial layer is another hallmark of progressed plaque (Fleiner et al., 2004). Hyperplastic 
network of vasa vasorum and ectopic neovascularization of the plaque are associated with 
intimal thickening, lipid contents and the degree of inflammation (Fleiner et al., 2004). The 
extent of these microvessels delivers a channel for entry of inflammatory cells into the 
plaque, boosting inflammation even more (Lusis, 2000). This blood vessel networks are 
fragile and prone to rupture and create an outward expansion of intraplaque hemorrhage 
that may overwhelm the integrity of the fibrous cap (Dickson & Gottlieb, 2003). 
Thrombogenic property of lipid-rich necrotic core is determined by its collagen and tissue 
factor content. Two important direct platelet agonists dwell in the lipid-rich core, i.e 
lysophosphatidic acid which mediates platelet shape change during thrombus formation 
and collagen which induces platelet adhesion and aggregation (Lusis, 2000). Tissue factor, 
another major thrombogenic subtrate in the lipid-rich core, is released by endothelial cells, 
smooth muscle cells, monocytes and macrophages or foam cells (Moons et al., 2002). The 
most abundant tissue factor site is in the necrotic core (Moons et al., 2002).  Tissue factor 
activates coagulation cascade and promotes thrombus stabiliy through fibrin network 
formation. Platelets are also capable in releasing tissue factor which give a hint of their role 
in supporting coagulation process (Zillmann et al., 2001). 
3.2 Platelet-endothelial interaction promotes progressed plaque 
Platelets have two storage granules, alpha and dense granules. Alpha granules contain 
adhesion molecules, chemokines, coagulation and fibrinolysis proteins, growth factors, 
and other proteins (Linden & Jackson, 2010). Dense granules contain molecules such as 
calcium, magnesium, phosphate and pyrophosphate, adenosine and guanosine 
triphosphate, adenosine and guanosine diphosphate and serotonin (Linden & Jackson, 
2010). These granules develop in megakaryocytes, the progenitor cell of platelets. Platelet 
also contains lysosomes which have ubiquitous lysosomal membrane proteins: LAMP-1, 
LAMP-2, and CD63 (LAMP-3), acid hydrolases, cathepsins and other proteins (King & 
Reed, 2002). 
In the alpha granules, platelet-specific proteins are synthesized only in megakaryocytes and 
deliver to platelets which undergo proteolytic upon platelet activation, which include 
platelet factor 4 (PF-4) and ┚-thromboglobulin (King & Reed, 2002). Platelet-selective 
proteins are synthesized principally by megakaryocytes but also in fewer number by few 
other cells and found in a larger concentration in platelets than plasma. These platelet-
selective proteins include coagulation factor V, thrombospondin, P-selectin, and von 
Willebrand factor (King & Reed, 2002).  
It is expected that platelets keep away from contact with vascular walls or other blood 
cellular components. Under steady laminar blood stream, platelets tend to flow away 
from endothelial cell surface area, avoiding connection with endothelial cells. 
Furthermore, intact and inactivated endothelial cell prevent platelet to adhere to its 
surface. Endothelial cells control platelet activity through inhibitory mechanisms 
involving cyclooxigenase 2 (Cox-2), prostacyclin or prostanoid synthetic systems (Gawaz, 
2006). However, activated endothelial cells are capable to capture platelets and activated 
them, even without any endothelial damage (intact endothelial cells). Activated platelets 
will express several molecules, release their granule contents and stimulate surrounding 
cells, thus promoting plaque progression.  
www.intechopen.com
 Plaque, Platelets, and Plug – The Pathogenesis of Acute Coronary Syndrome 
 
81 
3.2.1 Rolling and adhering of platelet to endothelial cell surface 
During inflammation, endothelial cells are activated and change their phenotype becoming 
prone to be adhesive for platelets (Gawaz, 2006). In vitro experiment showed that platelets 
adhere to activated human umbilical vein endothelial cells (HUVEC) which is mediated by 
fibrinogen, fibronectin and von Willebrand factor bound to platelets and endothelial cell 
receptors, ICAM-1, integrin ┙v┚3 and GPIb (Bombelli et al., 1998). In vivo experiment 
discloses that loose contact between platelets and activated endothelial cells precedes a 
tighter adhesion (Frenette et al., 1995). Rolling of platelets to activated endothelial cell is 
mediated by endothelial P-selectin and constitutively-expressed platelet P-selectin 
glycoprotein ligand 1 (PSGL-1) (Frenette et al., 1995; Frenette et al., 2002).  
P-selectin is a type-1 membrane glycoprotein with a C-type lectin domain and is stored in 
the Weibel-Palade bodies of endothelial cells and alpha granules of platelets (Furie & Furie, 
1995). It rapidly translocate to cell membrane upon endothelial cell or platelet activation 
(Frenette et al., 2002). PSGL-1 is an adhesion molecule primarily expressed in myeloid cells 
and T cells and functions as the main P-selectin ligand which mediates interactions between 
myeloid cells and endothelial cells as well as between myeloid cells and platelets 
(Vandendries et al., 2004). In the study of apoE-knock-out and the P-selectin gene deletion 
mice, atherosclerotic lesion development was significantly delayed, indicating the role of P-
selectin as a key adhesion receptor in promoting advanced atherosclerosis (Dong et al., 
2000). In early atherogenesis, it is likely that intact endothelial cells activate quiescent 
platelets through rolling mechanism via endothelial cell P-selectin and platelet PSGL-1 
interaction. Endothelial cells coating atherosclerotic plaque are constantly under activated 
state, thus expressed P-selectin and attract platelets. P-selectin-expressed activated platelets 
bind to activated endothelial cells in a greater amount than non-activated platelets do.  
In addition to platelet PSGL-1, platelet GP1b┙ is capable to interact with endothelial P-
selectin and mediate platelet rolling (Gawaz et al., 2006). GP1b┙ is a component of  GP Ib-
IX-V complex which comprises four polypeptides: GP Ib┙, GP Ib┚, GP IX, and GP V (Romo 
et al., 1999).  GP Ib-IX-V complex bind to subendothelial von Willebrand factor, exposed 
when endothelial cell disrupted and initiate thrombosis. GP1┙ contains von Willebrand 
factor–binding site and molecular structure nearly similar to PSGL-1 (Romo et al., 1999). 
Consequently, during endothelial cell activation, in addition to P-selectin, von Willebrand 
factor are also released from Weibel Palade body to the surface cell membrane. Both 
endothelial cell P-selectin and von Willebrand factor become the target for platelet GP1b┙ 
(Theilmeier et al., 2002). A study using mice deficient of von Willebrand factor showed some 
level of protection from atherosclerosis thus elucidated the role of von Willebrand factor on 
plaque formation and progression in intact endothelial cells (Methia et al., 2001).  
3.2.2 Tight adhesion of platelet to endothelial cell surface 
P-selectin-mediated loose contact is subsequently changed by tighter connection involving 
endothelial cell integrin, ┙v┚3 and platelet integrin, ┙IIb┚3 (Langer & Gawaz, 2008). 
Ligation of platelet GPIb┙ to endothelial cell von Willebrand factor during platelet rolling 
lead to activation of platelet integrin (Kasirer-Friede et al., 2002). Integrins are ubiquitous 
transmembrane ┙/┚ heterodimers that mediate cell-matrix and cell-cell interactions 
(Bennet, 2005). Platelets express 3 members of the ┚1 subfamily (┙II┚1, ┙v┚1, and 
┙vI┚1) and 2 members of the ┚3 subfamily (┙v┚3 and ┙IIb┚3) (Bennet, 2005). An ┙IIb┚3 
is the most important integrin on platelets (Gawaz et al., 1991). In vitro and in vivo studies 
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show that platelet ┙IIb┚3 and endothelial cell ┙v┚3, mediate firm contact between platelets 
and activated endothelial cells (Bombeli et al., 1998; Maasberg et al, 1999). By forming a 
bridge to fibrinogen, ┙IIb┚3 promotes arrest of platelets to adhesion molecules, intercellular 
adhesion molecule-1 (ICAM)-1, and to ┙v┚3 on activated endothelial cells (Bombeli et al., 
1998; von Hundelshausen & Weber, 2007). Fibrinogen links platelet fibrinogen receptor on 
the surface of ┙IIb┚3 to the endothelial cell ┙v┚3 and forms the firm platelet adhesion to 
activated endothelial cells (Gawaz et al., 1991).  
 
 
Fig. 1. Rolling of platelets to endothelial cells is mediated by platelet PSGL-1 and GP1b┙ 
bind to endothelial cell von Willebrand factor and P selectin. 
It is worth mentioning that interaction between platelets and activated endothelial cells is 
not sufficient to promote thrombus formation. However, platelet adhesion to endothelial 
cells contributes to the progression of the plaque. Platelets mediate such effects through 
releasing products following adhesion and activation. The contents of storage granules are 
liberated upon platelet activation. It is estimated more than 300 proteins are secreted from 
activated platelets, which act in an autocrine or paracrine manner to modulate cell signaling 
and mediate the plaque progression (Coppinger et al., 2004).   
Endothelial cell chemotactic, adhesion, and proteoliytic capacities are altered by paracrine 
modulation of substances released by adherent activated platelets. Here are the lists of 
platelet contents released upon adhesion and activation : (1) adhesion proteins (e.g., P-
selectin, vitronectin, fibrinogen, fibronectin, von Willebrand factor, thrombospondin and 
┙IIb┚3), (2) growth factors (e.g., PDGF, TGF-┚, EGF and bFGF), (3) chemokines (e.g. 
RANTES, PF-4 and epithelial-neutrophil activating protein 78 (ENA-78)), (4) cytokine-like 
factors (e.g. IL-1┚, CD40 ligand and ┚-thromboglobulin) and (5) coagulation factors (e.g. 
factor V, factor XI, PAI-1, plasminogen and protein S) (Gawaz et al., 2005). 
In vitro study revealed that activated platelets coincubated with cultured endothelial cells 
gave rise to a secretion of MCP-1 and surface expression of ICAM-1 and ┙v┚3 on endothelial 
cells, which is mediated by an IL-1-dependent mechanism (Gawaz et al., 2000). MCP-1 is an 
effectual chemotactic factor for monocytes and ICAM-1 is an adhesion molecule which 
advocates monocyte and neutrophil recruitment to endothelial cells. This study emphasized 
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the important role of IL-1┚ on mediating endothelial cell activity upon platelet activation. 
IL-1 is the prototypic cytokine released by inflammatory cells and three members of the IL-1 
gene family have been identified: IL-1, IL-1┚, and IL-1 receptor antagonist (IL-1RA) (von 
Hundelshausen & Weber, 2007). Platelet activation induces rapid and persistent synthesis 
and release of IL1┚ and converts endothelial cell phenotype to become more adhesive to 
circulating neutrophils (Lindemann et al., 2001). Inhibition of ┚3 integrin attenuated the 
synthesis of platelet IL-1┚, indicating firm adhesion of platelet to endothelial cells is 
prerequisite for IL-1┚ sustained secretion (Lindemann et al., 2001).  
 
 
Fig. 2. Tight adhesion of platelets to endothelial cells is mediated by platelet ┙IIb┚3 bind to 
endothelial cell ┙v┚3, bridged by fibrinogen, and ICAM-1. This results in release of platelet 
contents (blue dots) which mediates endothelial activated molecules (green dots) expression,    
Upon activation, platelet expresses CD40 ligand (CD40L) which ligates CD40 expressed by 
activated endothelial cells (Henn et al., 1998). Platelet CD40L and endothelial cell CD40 
interaction amplifies the release of IL-8 and MCP-1 from endothelial cells and enhances 
the expression of endothelial cell adhesion receptors including E-selectin, VCAM-1, and 
ICAM-1 (Henn et al., 1998). In vivo study using mice deficient of platelet CD40L shows that 
platelet CD40L accelerate plaque formation and progression, mainly due to prevention of 
leukocyte recruitment (Lievens et al., 2010). This study implicates that platelet CD40L is 
important for recruitment of monocytes, neutrophils and lymphocytes during plaque 
intitiation and progression. Ligation of CD40L on endothelial cells promotes endothelial cell 
tissue factor expression, thus enhances a procoagulant phenotype on endothelial cells 
(Slupsky et al., 1998). Furthermore, it implicates in both the generation and secretion of 
matrix metalloproteinase-9 (MMP-9) and protease receptor urokinase-type plasminogen 
activator receptor (uPAR), thus promotes proteolytic activity on endothelial cells (May et 
al., 2002). Tight adhesion of platelet to endothelial cell via ┙IIb┚3 binding enhances platelet 
CD40L upregulation and matrix degradation (May et al., 2002). This endothelial-mediated 
matrix degradation is important in digestion of fibrous cap, thus promotes imbalance of 
matrix production and degradation and subsequently weakens the cap. This contributes to 
loss of cap protection and threatens plaque in rupture-prone condition. 
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PF-4, stored in platelet alpha granules, is the most abundant protein secreted by activated 
platelets. In histopathological study on human carotid atherosclerotic, PF-4 accumulates 
within macrophages of the plaque in the early lesion and continues to accumulate in foam 
cells and neovascular endothelial cells as lesion progressed (Pitsilos et al., 2003). PF-4 is 
deposited on the endothelial cell surface and retained by subendothelial proteoglycan 
(Aidoudi & Bikfalvi, 2010). PF-4 can activate endothelial cells by stimulating E-selectin 
expression (Yu et al., 2005). In vitro study indicates that PF-4 inhibits apolipoprotein B-
containing LDL catabolism and facilitates retension of LDL on cell surface (Sachais et al., 
2002). PF-4 blocks LDL uptake by LDL receptor expressed by vascular wall cells, thus 
increases its retention and prolongs its residence time in the vascular space which allows 
apolipoprotein-B to be modified and increases ox-LDL deposition (Nassar et al., 2002).  
RANTES, secreted by activated platelets, triggers monocyte arrest and recruitment under 
flow conditions in vitro and in perfused carotid arteries (von Hundelshausen et al., 2001). 
Platelet P-selectin is important mediator of RANTES upregulation, indicates that RANTES is 
secreted during platelet rolling to endothelial cells (Schober et al., 2002). In atherosclerotic 
lesions and injury of apolipoprotein-E deficient mice, RANTES is expressed on endothelial 
cells (von Hundelshausen et al., 2001). Endothelial cells should have been modified by IL-1┚, 
in order to receive the deposition of RANTES (Weyrich et al., 2002).  Taken together, 
platelet-generated RANTES involves in atherosclerosis early in the beginning and more 
prominently in the plaque progression by modulating intimal hyperplasia and monocyte 
recruitment (Schober et al., 2002). Initial knowledge of ENA-78 activity is that this CXC 
chemokine superfamily member is synthesized and secreted by activated endothelial cells 
which give a proadhesive activity for neutrophils (Walz et al., 1997).  Activated platelet 
expresses ENA-78 which attract leukocyte to adhere the endothelial cells (Schober et al., 
2002). Furthermore, activated platelet-induced IL-1┚ action can stimulate endothelial cells to 
secret ENA-78 which encourage endothelial cell adhesiveness (Weyrich et al., 2002).   
3.3 Platelet-leukocyte interaction enhances progressed plaque 
Migration and recruitment of leukocytes into atherosclerotic plaque are essential steps of 
atherosclerosis progression. Leukocytes are captured and begin rolling on P-selectin 
expressing-endothelial cells. Leukocytes express PSGL-1 which engages in leukocyte rolling 
and attachment to P-selectin. Similar to that of platelet, P-selectin-mediated leukocyte 
binding to endothelial cells is a loose contact. This connection mediates rolling of leukocytes 
on the endothelial surface without firm attachment.   
In addition to direct contact between leukocytes and endothelial cells, activated platelets 
interact with leukocyte as well. Among leukocytes, monocytes and lymphocytes are the first 
to be involved in atherogenesis and plaque progression.   
3.3.1 Activated platelets bind and promote monocyte activation and transmigration  
Monocytes are predominant leukocytes lodge in atherosclerotic plaque.  Adherent platelets 
efficiently mediate monocyte rolling and arrest, even at high shear rate. Monocyte rolling is 
mediated by P-selectin on activated platelets and PSGL-1, constitutively expressed on 
monocytes (Kuijper et al., 1998). CD15, expressed by  monocytes, has also been shown to 
bind platelet P-selectin (Larsen et al., 1990).  
The initial connection between platelet P-selectin and monocyte PSGL-1 and CD15 is a loose 
attachment, and within rapid periode it leads to elevated expression of the monocyte 
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integrin ┙M┚2 (membrane-activated complex 1 (Mac-1)) and makes tighter adhesion which 
support binding to platelet (Neumann et al., 1999). Monoctyte Mac-1 has several counter-
receptors expressed on activated platelet, such as GP1b, JAM-3 and ICAM-2 (Simon et al., 
2000; Santoso et al., 2002; Diacovo et al., 1994).  
Platelet junctional adhesion molecule (JAM) supports platelet chemokine deposition and 
promotes monocyte recruitment (von Hundelshausen & Weber, 2007). JAM-3 is identified as 
a counter-receptor on platelets for the monocyte Mac-1 and mediates platelet-monocytes 
interactions (Santoso et al., 2002). Mac-1 is also able to bind indirectly to platelet ┙IIb┚3 
linked by soluble fibrinogen bridge (Gawaz et al., 1991). Furthermore, several protein-
receptor complexes mediate platelet-monocyte adhesion, such as thrombospondin which 
form a bridging of the CD36-CD36 interaction in both monocytes and platelets, CD40L on 
the platelet which attach to monocyte CD40 and monocyte triggering receptor expressed on 
myeloid cell 1 (TREM-1) to platelet-expressed TREM-1 ligand (Van Gils et al., 2009).  
The attachment of activated adherent platelets to monocytes induces monocyte activation 
through shedding, expressing and releasing fungsional proteins. Interaction between 
platelets and monocytes increases the expression and activity of chemotaxis (MCP-1 and 
MIP-1┙), proteolysis (uPAR and MMP), thrombosis (tissue factors), activation (TNF-┙ and 
IL-8) and adhesion (Mac-1 and VLA-4) factors on monocytes as well as potentiates 
monocyte to macrophage differentiation (Gawaz et al., 2005). In this respect, platelet-
monocyte interaction provides an atherogenic environment at the vascular wall that 
supports plaque formation and regression (Gawaz et al., 2005). Similar to adherent platelets, 
activated platelets circulating in blood stream can affect endothelial cell and leukocyte 
phenotype (Huo et al., 2003). Circulating activated platelets are detected in the blood of 
patients with atherosclerotic conditions, such as acute coronary syndromes (Sarma et al., 
2002), stable coronary disease (Furman et al., 1998), and diabetes mellitus (Broijersen et al., 
1998).   
In vitro study shows that platelet P-selectin increases monocytoid cell adhesion to 
endothelial cells (Theilmeier et al., 1999). In vivo study using apoE-knock-out mice reveals 
that circulating activated platelets, through platelet P-selectin, promote monocyte 
recruitment to atherosclerotic plaque and accelerate the formation of atherosclerotic lesions 
(Huo et al., 2002). Platelet P-selectin-mediated interactions lead to deposition of platelet-
derived proinflammatory factors, RANTES and PF-4, to the vessel wall and monocytes, 
resulting in activation of monocyte integrins, increased monocyte recruitment and accelerate 
atherosclerosis (Huo et al., 2002). Inversely, at low levels, activated endothelial cells express 
PSGL-1 and bind P-selectin on platelets and monocytes, thus mediating monocyte tethering 
and platelet recruitment to the endothelial cells (Da Costa Martins, 2007). 
Not only do adherent platelets form tight binding to monocyte, but also circulating 
activated platelets attach to monocyte and form platelet monocyte complex (PMC). PMC 
reflected great capacity of platelet activation and in lesser extent, monocyte activation (Van 
Gils et al., 2009). Activated platelets bind via P-selectin to its receptor on monocytes, PSGL-
1, and form complexes (Van Gils et al., 2009). PMCs mediate monocyte tethering and 
adhering to endothelial cell surface, making adherent monocyte-PMC cluster and promoting 
monocyte, and probably platelet,  transmigration into subendothelial plaque lession (Da 
Costa Martins et al., 2004).  PMC high adhesive capability to activated endothelial cell is due 
to increasing integrin activation on monocyte and subsequently, increasing cell adhesion to 
fibronectin, VCAM-1 and ICAM-1 (Da Costa Martins, 2006). Monocytes transmigrate into 
www.intechopen.com
  
Acute Coronary Syndromes 
 
86
the atherosclerotic plaque, and change phenotype, becoming macrophages which express 
scavenger receptors and digest oxLDL to become foam cells (Libby & Aikawa, 2001).  
 
 
Fig. 3. Activated platelets recruit monocytes via platelet P selectin binding to monocyte 
PSGL-1 and CD15, subsequently stabilized by monocyte Mac-1 bind to counter receptors in 
platelets thus promoting monocyte adhesion and transmigration into subendothelial.  
Monocytes are the main source of tissue factor, an important determinant of thrombogenic 
plaque (Lindmark et al., 2000). Along with more monocyte recruitment, macrophage 
proliferation and tissue factor production intensify, filling the plaque with inflammatory 
and thrombogenic material which promote plaque progression. 
3.3.2 Activated platelets bind and promote lymphocyte activation and transmigration  
Lymphocyte transmigration from circulation to atherosclerotic plaque follows three steps: 
selectin-mediated rolling, integrin-modulated adhesion and transmigration. The 
transmigration of all lymphocyte populations, i.e. T cells, B cells, and natural killer cells, are 
enhanced by activated platelets (Li, 2008). Activated platelets interact with lymphocytes 
through binding between platelet P-selectin and lymphocyte PSGL-1 forming  a loose 
contact, which subsequently induces clustering of ┙L integrin and enhances lymphocyte 
firm adhesion via ICAM-1 binding (Atarashi et al., 2005). Among lymphocytes, T cells have 
stronger adhesive capacity than B cells, indicates that T cells are selectively recruited in 
mediation of P-selectin expressing cells (Li, 2008) Enhancement of  T cell adhesion on 
subendothelial matrix is mediated by activated platelets through formation of platelet–T cell 
conjugates and via ligations of P-selectin, CD40L and ┙IIb┚3 integrins (Li, 2008).  
In progressed atherosclerotic plaque, T cells make up nearly 10% to 20% of the cell 
population and assemble at sites which are prone to rupture and cause fatal thrombosis 
(Hansson et al., 2002). Most of the T cells in atherosclerotic lesions is T helper (CD3+ and 
CD4+) and T-cell antigen receptor positive (TCR┚+), which indicate a function of 
recognition of antigens presented by macrophages or dendritic cells (Hansson et al., 2002). 
They modulate cell mediated immunity through secretion of interferon (IFN-┛), IL-2, and IL-
22 (Hansson et al., 2002). IFN-┛ inhibits smooth muscle cell new collagen synthesis, which is 
essensial in supporting fibrous caps, thus weakens fibrous cap and promotes rupture-prone 
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plaque (Libby et al., 2010). Smooth muscle cells in the rupture-prone plaque express HLA-
DR which is susceptible to IFN-┛ action (Libby & Aikawa, 2001). Furthermore,  activated T 
cells induce production of MMP and tissue factor, mediated by CD40-CD40L binding, which 
enhances the thrombogenicity of the plaque lipid-rich core (Libby  et al., 2010).   
4. Activated platelet plays important role in coronary atherothrombosis  
Arterial thrombosis is the acute complication that develops on the chronic atherosclerosis 
lesion, i.e. atherothrombosis, and in the coronary artery it causes acute coronary syndromes, 
during which blood flow through coronary segment is partially or totally obstructed. 
Platelets are prominent constituents of the thrombi that occlude the lumen of arteries. In this 
regard, atherothrombosis is a term that describes the combination of acute, a complication, 
and chronic, a progression, events of arterial disease (Ruggeri, 2002). Platelets are involved 
in both processes, through promoting plaque progression and participating in ruptured 
plaque-driven thrombus formation (Ruggeri, 2002).  
Inducing event of acute coronary syndrome is plaque rupture or erosion. Rupture of fibrous 
cap lining the plaque is account for 60–65% of occlusive thrombi and erosion of endothelial 
cells lining the plaque is responsible for the rest 35–40% (Dickson & Gottlieb, 2003). In the 
rupture-prone atherosclerotic plaque, fibrous cap maintains protective role for the integrity 
of the plaque and provides a barrier between the thrombogenic material in the necrotic core 
and circulating blood components, mainly platelets and coagulation factors (Libby & 
Aikawa, 2001). As plaque progressed, leukocyte-driven inflammation is heightened in the 
intimal layer. Inflamed leukocytes can hinder biosynthesis of collagen from smooth muscle 
cells and can themselves overexpress collagen-degrading proteinases which in turn give the 
condition of the imbalance between collagen synthesis and degradation, thus weakening the 
fibrous caps and lead to plaque rupture (Libby & Aikawa, 2001). Furthermore, leukocytes 
participate in augmentation the production of the procoagulant factor, primarily tissue 
factor, in plaque lesion and give rise to the high thrombogenicity of the plaque’s lipid core 
(Libby et al., 2010). In addition to intrinsic factor within plaque, vessel lumen shear stress 
contribution for rupture of the plaque is considerate as well, since lumen restricted-area 
surrounding the plaque causes a local rising in blood flow velocity. Wall shear rate may 
exceed considerably at the edge of a severe occlusion in a coronary artery. High shear stress 
may specifically enhance platelet reactivity to matrix extra cellular of plaque (Ruggeri, 2002).    
The main trigger for the formation of a thrombus is the loss of the endothelial cell barrier 
and exposure of thrombogenic subendothelial extracellular matrix components with 
circulating blood. The response of platelets to this event can be divided into three successive 
but closely integrated phases: adhesion, activation and aggregation (Ruggeri, 2002). Several 
indices of activated platelets in the circulating blood are increased in patients with coronary 
artery disease and acute coronary syndromes, such as platelet surface molecule expression, 
platelet-monocyte aggregates, platelet-neutrophil aggregates and soluble proteins releasing 
upon platelet activation, mainly soluble CD40L (sCD40L) (Linden et al., 2007; Setianto et al., 
2010). 
4.1 Platelet tethering and adhesion initiate atherothrombosis   
Erosion or rupture of the plaque poses circulating platelets, some of them have already 
activated, with highly thrombogenic extra cellular matrix components of the lipid core 
www.intechopen.com
  
Acute Coronary Syndromes 
 
88
which contains several adhesive molecules such as collagen, von Willebrand factor, laminin, 
fibronectin and thrombospondin (Andrews & Berndt, 2004). These molecules, once exposed, 
provide ligands for various activated platelet surface receptors. Under low shear rate 
condition, such as in vein and large artery flow, the molecules bind to platelet receptors are 
collagen, fibronectin and laminin, whereas under higher shear rates, such as in small arteries 
and atherosclerotic vessel, collagen and von Willebrand factor are principal molecules to 
mediate platelet slackening, tethering and adhesion (Andrews & Berndt, 2004). The early 
step of atherothrombosis is tethering of platelets to the surface of rupture plaque and is 
accomplished through the interaction between platelet GPIb┙ and collagen-bound von 
Willebrand factor (Ruggeri, 2002) and platelet GPVI and collagen (Andrews & Berndt, 2004).  
GPIb┙ is the major ligand-binding subunit of GPIb-IX–V or von Willebrand factor receptor 
and, in addition to binding site for von Willebrand factor, contains partially overlapping 
binding sites for the leukocyte integrin Mac-1, ┙-thrombin, and P-selectin expressed on 
activated platelets or activated endothelial cells (Andrews & Berndt, 2004). GPVI is a 
collagen receptor of the immunoglobulin superfamily that forms a complex with the FcR g-
chain at the cell surface in human and mouse platelets (Andrews & Berndt, 2004). 
Von Willebrand factor, stored both by alpha granules of platelets or Weibel-Palade body of 
endothelial cells, is an adhesive glycoprotein found in circulating blood or subendothelial 
matrix (Andrews & Berndt, 2004). Circulating von Willebrand factor, which amount is much 
higher than that in subendothelial matrix, can be immobilized in exposed collagen via 
collagen binding site and become the substrate for platelet GP1b┙ (Massberg et al., 2003). In 
addition to collagen-bound, circulating von Willebrand factor can also be immobilized by 
forming the multimeric connection to matrix-bound, platelet-bound or subendothelial von 
Willebrand factor (Ulrichts et al., 2005). Immobilized von Willebrand factor is capable to 
catch circulating platelets via binding with platelet GPIb┙ (Andrews & Berndt, 2004). 
Ligation of non-activated platelet GPIb┙ with collagen-bound von Willebrand factor is not 
stable enough and is intended mainly to slow down platelets and maintain them in the 
rupture site, where subsequently platelets will be activated through various receptors, 
mainly integrin, and stable adhesion is formed.  
 
 
Fig. 4. Plaque rupture exposes platelets to thrombogenic collagen which attract them to 
adhere via platelet GPVI bind to collagen and GP1b┙ bind to collagen-bound von 
Willebrand factor, initiate thrombus formation. 
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In addition to collagen-bound von Willebrand factor, collagen itself can capture non-
activated circulating platelets through platelet GPVI. However, GPVI has only a low affinity 
for collagen which makes GPVI, same as GPIb┙, incapable to mediate stable platelet 
adhesion. Ligation of GPVI during the initial contact between platelets and subendothelial 
collagen provides an activation signal through platelet integrins, ┙IIb┚3 and ┙2┚1, which is 
essential for subsequent stable platelet adhesion and aggregation (Gawaz, 2004). Although 
not tightly adherent, this early adhesion of platelets is of adequate affinity to facilitate arrest 
at high shear rate, leading ultimately to much more stable integrin-mediated adhesion 
(Andrews & Berndt, 2004). 
4.2 Platelet activation and aggregation enhance atherothrombosis  
Platelet activation and aggregation are the ensuing steps that occur within minutes, marked 
by the accumulation of platelets into the haemostatic thrombus (Ruggeri, 2002). Collagen-
bound von Willebrand factor and platelet GPIb┙ interaction convey signal activation of 
platelet integrin ┙IIb┚3 to undergo conformational changes which are compulsory for firm, 
irreversible platelet resting on the subendothelial matrix surface (Gawaz, 2004). 
Conformational changes of ┙IIb┚3 enable an exposure of fibrinogen binding site which form 
cross linking with ┙IIb┚3 on different platelets by fibrinogen bridge (Andrews & Berndt, 
2004). Similarly, ligation of GPVI shifts platelet ┙IIb┚3 and ┙2┚1 from a low to a high affinity 
state and contributes to stable platelet adhesion (Gawaz, 2004). Until this step, stable 
adhesion of platelets is promoted by irreversible binding of platelet ┙IIb┚3 to collagen-
bound von Willebrand factor and platelet ┙2┚1 to uncoated collagen. The integrin-
dependent stable adhesion of platelets consequently leads to activation of adherent platelets.  
Activated platelets are receptive to wide range of agonists or stimulants and adhesive 
proteins. They express surface receptors, which, upon activation by agonists and adhesive 
proteins, stimulate internal signaling pathways that lead to further platelet activation, 
degranulation, and capacity enhancement to bind with other adhesive proteins or platelets. 
Transmembran receptors are the main agonist-stimulated receptor families and greatly 
activated during thrombus formation. The important platelet receptors in this class are 
thrombin receptors (protease activation receptor (PAR-1 and PAR-4), ADP receptors (P2Y1, 
and P2Y12) and integrins (mainly ┙IIb┚3) (Freedman, 2005). 
Activation of platelets by thrombin through PAR-1 and PAR-4 receptors results in calcium 
flux, platelet shape change, and stimulation of a variety of platelet-signaling pathways 
(Freedman, 2005). Importantly, thrombin-PAR receptor interaction leads to activation of 
integrin ┙IIb┚3 receptor complex through inside-out signalling (Freedman, 2005).  
In non-activated platelets, ┙IIb┚3, the most abundant platelet integrins, has a very low 
affinity for its ligands (Cosemans et al., 2008). However, platelet activation remarkably 
increases the capacity of ┙IIb┚3 to attach to its ligands, particularly fibrinogen, fibrin, 
fibronectin and von Willebrand factor (Cosemans et al., 2008). These soluble adhesive 
proteins are immobilized and are attached to activated ┙IIb┚3 on the surface of activated 
adherent platelets and become the substrate for more non-activated circulating platelet 
recruitment and aggregation (Ruggeri, 2002). The interaction of circulating platelets with 
adherent platelets carries on through activated ┙IIb┚3 cross linking between platelets 
bridged by soluble fibrinogen, thus form the platelet aggregates (Gawaz, 2004). Platelet 
activation increases the surface density of ┙IIb┚3, thus more soluble fibrinogen attach and 
bridge other platelets, makes cross linking and allows continuing platelet aggregation and 
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thrombus growth. The inhibiton of interaction of platelet ┙IIb┚3 - von Willebrand factor and 
┙IIb┚3 - fibrinogen by ┙IIb┚3 antagonists, i.e tirofiban, abciximab and eptifibatide, is of 
potentially benefit in acute settings of coronary atherothrombosis, due to inhibition of 
platelet aggregation, thrombus growth  and stability.  
 
 
Fig. 5. Adhesion and activation of platelets form stable plug via platelet ┙IIb┚3 bind to 
collagen-bound von Willebrand factor and platelet ┙2┚1 bind to collagen, thus stimulate 
release of platelet surface receptors (blue dots) receptive to agonists and adhesive proteins.  
In addition to integrin activation, several means of activation responses of platelets include: 
mobilization of cytosolic calcium, secretion of ADP, shedding and secretion of CD40L, 
released of tromboxane A2 (TxA2) and formation of pseudopods which support an effective 
sealing of the denuded plaque area (Cosemans et al., 2008; Gawaz, 2004). ADP, secreted by 
dense granules of activated platelets, stimulates platelets in autocrine loop through its 
receptors, P2Y1 and P2Y12. P2Y1 activation mediates platelet shape change and initiates 
platelet aggregation by mobilization of intracellular calcium (Andre et al., 2003). P2Y12 
activation by ADP signal mediates inhibition of adenylyl cyclase and stabilizes platelet 
aggregates as well as participates in the firm adhesion by activating ┙IIb┚3 (Andre et al., 
2003). Persistent signal to keep P2Y12 in active state is of paramount important to prevent 
platelet disaggregation and to maintain ┙IIb┚3 in its active conformation (Cosemans et al., 
2008). In addition to autocrine loop, ADP also works in paracrine mechanism by stimulating 
and recruiting non activated circulating platelets and inducing them to undergo aggregation 
with adherent platelets (Gawaz, 2004). Antagonist for P2Y12, i.e ticlopidine and clopidogrel, 
has already been widely used in acute coronary syndrome.  
CD40L, expressed and released by activated platelets, binds to activated ┙IIb┚3 and 
contributes in supporting platelet aggregate stability (Andre et al., 2002). Upon platelet 
activation, the cytosolic CD40L protein is exocytosed to the platelet plasma membrane from 
where it is also shed and release into circulation in soluble form, sCD40L (Andre et al., 2002). 
These transmembran and soluble forms are detected to be elevated in patients with acute 
coronary syndrome (Aukrust et al., 1999; Garlichs et al., 2001; Setianto et al., 2010). Both 
transmembrane and soluble CD40L can form a cluster with platelet ┙IIb┚3 and lead to more 
platelet activation and enhance thrombus formation and stabilization (Andre et al., 2002).  
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TxA2 is made from arachidonic acid and is secreted by activated adherent platelets. It 
strengthen the activation process after the release into the extracellular space and create 
platelet feedback activation by acting as autocrine and paracrine manner on its thromboxane 
platelet receptor (Gawaz, 2004). TxA2 has a vasoconstricting activity and thus favors 
formation of the thrombus by slowing down the blood flow (Gawaz, 2004).  Aspirin induces 
a complete and permanent inhibition of platelet TxA2 production through the inactivation 
of cyclooxygenase. In addition to ┙IIb┚3-mediated stability, several other adhesion and 
signaling receptors contribute to thrombus stability, such as PECAM-1, JAM-A, JAM-C, 
ESAM, CD226, and  Epf kinases/ephrins, which is enable the tight contact of one platelet 
with receptors on adjacent platelets (Brass et al., 2005).  
5. Conclusion 
Platelet is a key maker for progression of atherosclerotic plaque. Its ability to interact with 
activated endothelial cells and leukocytes, provide the milieu of inflammation and 
thrombus-prone environment in atherosclerotic plaque. Platelet, with relatively similar 
pattern, captures monocyte and lymphocyte and grants them the path to transmigrate into 
atherosclerotic plaque. Platelet is a central player during coronary plaque rupture. It starts 
and nurtures coronary thrombus formation and stabilization. Platelet-based therapeutic 
modalities for atherosclerosis and acute coronary syndrome are still in progressed studies 
with some of them yield beneficial effect while others inconclusive.  
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